Real-World Study Compares Tirzepatide and Semaglutide for Cardiovascular Risk

Individuals with Type 2 Diabetes and overweight or obesity often face elevated cardiovascular (CV) risk, necessitating effective treatment strategies. While randomized controlled trials (RCTs) establish drug efficacy, real-world data (RWD) is crucial for understanding comparative effectiveness in diverse patient populations. This study, part of the RCT-DUPLICATE initiative, addresses the critical need for empirical evidence on the comparative effectiveness of newer antidiabetic medications using large-scale, real-world insurance claims data.